Clinical trials: COVID19 ARDS
Covid-19, ARDS
Timing of Tracheotomy in Covid-19 Patients
Critically ill covid-19 patients may require respiratory support including mechanical ventilation. After an initial period with an endotracheal tube, a tracheotomy is performed in order to reduce potential airway complications…
- Conditions
- Covid-19, ARDS, Tracheostomy Complication, Respiratory Insufficiency
- Trial name
- TTCOV19 (NCT04412356)
- Testing
- Tracheotomy
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Sahlgrenska University Hospital
COVID-19, COVID-19 Pneumonia
Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients
Check the efficacy, safety and tolerability of the compound Modified isothymol against the SARS-CoV-2 agent in patients COVID-19.
- Conditions
- COVID-19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05445089
- Testing
- Carvacrol, Control group
- Where
- Venezuela
- Volunteers
- 600 people
- Sponsor
- Instituto Venezolano de Investigaciones Cientificas
Severe Acute Respiratory Syndrome Coronavirus 2
Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection
It is an observational, cohort, retrospective, monocentric, non-profit study. The primary objective is to evaluate the efficacy and safety of ruxolitinib in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19…
- Trial name
- RESPIRE (NCT04361903)
- Testing
- Ruxolitinib Oral Tablet
- Volunteers
- 13 people
- Sponsor
- Azienda USL Toscana Nord Ovest
ARDS, Sars-CoV-2 Infection
Physiological Response to Prone Position in COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)
Retrospective study in COVID-19 ARDS patients hospitalised in the ICU. Investigators aim to explore the effects of prone positioning on oxygenation, dead space ventilation and mortality.
- Trial name
- NCT05092737
- Testing
- Prone positioning
- Where
- Switzerland
- Volunteers
- 31 people
- Sponsor
- University of Lausanne Hospitals
Covid19, ARDS
Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
In this study, the investigators are attempting to evaluate the influence of socio-economic factors on the functional recovery (physical and psychological) of patients who developed ARDS after a COVID-19 infection, with the aim…
- Conditions
- Covid19, ARDS, Functional Recovery
- Trial name
- RECOVIDS (NCT04556513)
- Testing
- Paraclinical examination, Clinical Examination, Semi-directive interview
- Where
- France
- Volunteers
- 543 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19 Acute Respiratory Distress Syndrome
Pulmonary Inflammation in COVID-19 ARDS
Patients older than 18 years of age, with COVID-19 related ARDS (C-ARDS) hospitalized in the ICU and invasively mechanically ventilated will be included in the study. This is an observational cohort study.
- Trial name
- IMPU-COVID (NCT04935450)
- Testing
- Bronchoalveolar lavage
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Hospital Universitario Ramon y Cajal
Diaphragm Injury, Pathology
Effects of Mechanical Ventilation on the Diaphragm in COVID-19 Intensive Care Patients. A Post-mortem Pathology Study
The diaphragm is the fundamental muscle of the respiratory system. The diaphragmatic dysfunction is present in 60% of critical patients at hospital admission and up to 80% after prolonged mechanical ventilation and difficult…
- Conditions
- Diaphragm Injury, Pathology, COVID-19 Acute Respiratory Distress Syndrome, Ventilation Therapy; Complications
- Trial name
- NCT05191433
- Where
- 2 sites in Italy
- Volunteers
- 41 people
- Sponsor
- Azienda Sanitaria-Universitaria Integrata di Udine
COVID
Pulmozyme to Improve COVID-19 ARDS Outcomes
This is a randomized double-blind placebo-controlled Phase II trial of recombinant human deoxyribonuclease I (rhDNase I) - Pulmozyme - in mechanically ventilated patients with COVID-19 pneumonia.
- Trial name
- NCT04402944
- Testing
- Pulmozyme
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Boston Children's Hospital
COVID-19 Acute Respiratory Distress Syndrome, Hypoxemia
Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia
This is an investigator initiated, single-center, open-label, Phase IIb clinical trial with 40 patients (for a total of 80 patients) to assess efficacy of Low molecular weight heparin using soft mist inhaler in the treatment of…
- Trial name
- NCT04990830
- Testing
- Inhaled Low molecular weight heparin, Standard Treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Istanbul University
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
In patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, the administration of Treg cells is a novel treatment complementary to other pharmacologic interventions that potentially…
- Trial name
- regARDS (NCT05027815)
- Testing
- Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Jeffrey Bluestone
Acute Respiratory Distress Syndrome, Covid19
Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome
The clinical picture of the novel corona virus 2 (SARS-CoV-2) disease (COVID-19) is rapidly evolving. Although infections may be mild, up to 25% of all patients admitted to hospital require admission to the intensive care unit…
- Trial name
- CIRCA-19 (NCT04400032)
- Testing
- Mesenchymal Stromal Cells
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Ottawa Hospital Research Institute
Survival, Prosthesis, Oxygen Deficiency
Awake Prone Positioning for COVID-19 Acute Hypoxaemic Respiratory Failure
The objective of our study is to evaluate the effectiveness of prone position in preventing intubation or death in spontaneously ventilated patients with COVID-19 with acute respiratory failure.
- Trial name
- NCT05866289
- Testing
- Prone position
- Where
- Morocco
- Volunteers
- 1,069 people, healthy volunteers welcome
- Sponsor
- Mohammed VI University Hospital
COVID-19, Hypoxia
Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
Previous research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS).
- Trial name
- AVoCaDO (NCT04357782)
- Testing
- L-ascorbic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Severe COVID-19 Disease
RAPA-501-Allo Therapy of COVID-19-ARDS
The first-in-human Phase 1 study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with COVID-19-related ARDS, with key endpoints of safety, biologic and potential disease-modifying effects.
- Trial name
- NCT04482699
- Testing
- RAPA-501-Allo off-the-shelf Therapy of COVID-19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rapa Therapeutics LLC
Anticoagulation in COVID-19 ARDS
Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial
Patients with COVID-19 associated ARDS and mechanical ventilation have a high mortality. Part of the disease is an activation of the coagulation system which seems to contribute to clotformation in the pulmonary bloodstream.
- Trial name
- NCT04445935
- Testing
- Bivalirudin Injection, Standard treatment
- Where
- Qatar
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
COVID-19, Pneumonia
Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia
To assess the clinical efficacy of ANG-3777 relative to the standard of care in reducing the severity and progression of pulmonary and renal dysfunction and mortality in adult patients hospitalized with COVID-19 pneumonia
- Trial name
- NCT04459676
- Testing
- Standard of Care (SOC) + ANG-3777
- Where
- 10 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Angion Biomedica Corp
ARDS, Human, COVID
Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
SARS-CoV-2, one of a family of human coronaviruses, was initially identified in December 2019 in Wuhan city. This new coronavirus causes a disease that has now been named COVID-19.
- Trial name
- COVIPOC (NCT04594668)
- Testing
- Senicapoc
- Where
- 4 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
COVID - 19, Acute Respiratory Distress Syndrome (ARDS)
Prone Duration in COVID-19 ARDS
The aim of this observational study is to learn the effects of prone position duration on patient outcomes in patients with severe acute respiratory distress syndrome (ARDS) due to Coronavirus Disease - 2019 (COVID-19).
- Trial name
- PRODUR-CARDS (NCT06765759)
- Where
- Turkey (Türkiye)
- Volunteers
- 79 people
- Sponsor
- Istanbul University - Cerrahpasa
COVID, Corona Virus Infection
Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms
The study is a prospective, randomized, controlled investigation designed for comparison of two groups for the reduction of respiratory distress in a CoViD-19 population, using gammaCore Sapphire (nVNS) plus standard of care…
- Conditions
- COVID, Corona Virus Infection, Respiratory Failure, Respiratory Distress Syndrome, Adult
- Trial name
- SAVIORII (NCT04382391)
- Testing
- gammaCore® Sapphire (non-invasive vagus nerve stimulator), Standard of care therapies
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Acute Respiratory Distress Syndrome, Coronavirus
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical…
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure
- Trial name
- VANGARD (NCT04433546)
- Testing
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.